Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.Earlier HIV treatment has particular benefits for people with HIV and...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Eliminating hepatitis C as a major public health threat needs a two-pronged attack

    So where do we stand on the road to elimination? Early indications suggest that improved access to treatment may already be having an impact with preliminary UK figures suggesting a 11% fall in deaths from hepatitis C related end-stage liver disease and cancer in 2015.

    18 October 2016 | Public Health England
  • Punjab hepatitis control programme on verge of collapse

    Punjab is facing a grave threat of Hepatitis C due to mismanagement of funds, as Rs 1,476 million have still not been utilised for the treatment of needy patients, raising serious question marks on the provincial government's health priority.

    18 October 2016 | Daily Times
  • People infected by hepatitis C in Canada have limited access to direct-acting antivirals

    A study conducted by researchers at the University of Montreal Hospital Research Centre (CRCHUM), The Kirby Institute at UNSW Australia, and the Canadian Network on Hepatitis C (CanHepC) shows that nearly everywhere in Canada, provinces and territories impose obstacles to the reimbursement of these medications by the public system because of their cost.

    17 October 2016 | CRCHUM Montreal
  • European regulator amends some Gilead hep C patent claims

    In a setback for Gilead Sciences, European regulators decided not to uphold all of its patent claims for the best-selling Sovaldi hepatitis C treatment, a move that could lead to generic versions of the medicine becoming available four years sooner than had been expected.

    06 October 2016 | STAT
  • HCV Drugs May Reactivate HBV, FDA Warns

    Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

    06 October 2016 | Medscape (free registration required)
  • UNITAID and FIND launch initiative to improve diagnostics and treatment for hepatitis C

    The US $38.3 million project will support the development of better, simpler, diagnostic tools for HCV where people seek care, and will introduce HCV testing and treatment over three and a half years in HIV programmes in seven countries: Cameroon, Georgia, India, Malaysia, Myanmar, Thailand and Vietnam.

    04 October 2016 | UNITAID
  • Elimination of viral hepatitis by 2030: What's needed and how do we get there?

    This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly. Currently, the available surveillance data show ongoing transmission of hepatitis in Europe and in order to interrupt this chain and to prevent further infections, European countries need to strengthen local prevention and control practices as outlined in the plan.

    04 October 2016 | European Centre for Disease Prevention and Control (ECDC)
  • Australia leading world in hepatitis C treatment; but disease more prevalent in Aboriginal people

    More people are on track to be cured of hepatitis C in Australia this year than over the past two decades combined, new research has shown.

    29 September 2016 | ABC Online
  • NICE says yes to another hepatitis C drug

    NICE has published new draft guidance which recommends sofosbuvir-velpatasvir (Epclusa) – an anti-viral drug that offers patients with chronic hepatitis C a potential cure.

    26 September 2016 | NICE
  • Exviera, Viekirax regimen shows high SVR in HCV genotype 1b after 8 weeks

    New data from the GARNET study — presented today in Paris at the 2016 EASL Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure — showed 98% of patients with hepatitis C virus genotype 1b infection without cirrhosis achieved sustained virologic response 12 weeks after treatment with Exviera plus Viekirax without ribavirin, with some showing high rates after 8 weeks.

    26 September 2016 | Healio
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap